Press Releases Choose Year All Items 2026 2025 2024 Search Press Releases Found 36 Results July 29, 2026 LB Pharmaceuticals Announces $150 Million Private Placement July 22, 2026 LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia July 10, 2026 LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) June 30, 2026 LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations May 28, 2026 LB Pharmaceuticals to Participate in Upcoming June Investor Events May 12, 2026 LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update April 22, 2026 LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia April 9, 2026 LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference March 27, 2026 LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) March 26, 2026 LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update 1234»
